<DOC>
	<DOCNO>NCT01085578</DOCNO>
	<brief_summary>Evaluation Safety , Tolerability Pharmacokinetic Characteristics CG400549 Healthy Volunteers</brief_summary>
	<brief_title>CG400549 Single Ascending Dose Study</brief_title>
	<detailed_description>This Phase 1 , 2-part study consist randomize , double-blind , placebo-controlled , single ascend dose ( SAD ) part ( 2 alternate panel ) 1-sequence food effect ( FE ) part . In SAD part , 2 cohort 6 healthy male subject receive single oral dose CG400549 placebo 3 period , randomize subject receive active treatment twice placebo ( period , 4 subject receive active drug 2 receive placebo ) . In FE part , 1 cohort 6 healthy male subject receive single oral dose CG400549 fast state Period 1 single oral dose CG400549 feed state Period 2 .</detailed_description>
	<criteria>1 . Sex : male 2 . Age : 1855 year , inclusive 3 . BMI : 1930 kg/m2 4 . Ability willingness abstain alcohol , methylxanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` powerdrinks '' ) , grapefruit ( juice ) tobacco product 48 h prior entry clinical research centre discharge 5 . Medical history without major pathology 6 . Normal blood pressure ( systolic 90140 mmHg ; diastolic 6090 mmHg ) heart rate ( 45 90 beat per minute ) ; minor deviation criterion could accept consider clinically insignificant Medical Investigator 7 . Computerised ( 12lead ) ECG record normal show clinically relevant deviation judge Medical Investigator 8 . Male subject female sexual partner must use doublebarrier contraception study period 90 day followup 9 . All value haematology clinical chemistry test blood urine within normal range show clinically relevant deviation judge Medical Investigator . In particular , liver enzyme ( aspartate aminotransferase [ ASAT ] alanine aminotransferase [ ALAT ] ) must within normal range creatine phosphokinase ( CPK ) must within 2.0 time normal range . 10 . Willingness sign write Informed Consent Form ( ICF ) 1 . Evidence clinically relevant pathology 2 . History bacterial viral infection require treatment antibiotic antiviral within 1 month study 3 . Presence history esophageal gastroduodenal ulceration within 1 month screening . 4 . Family history significant cardiac disease ( e.g. , sudden cardiac death myocardial infarction prior age 50 firstdegree relative ) 5 . Mental handicap , relevant cognitive psychiatric disorder history seizures 6 . History and/or presence relevant drug and/or food allergy 7 . Use concomitant medication , except acetaminophen ( paracetamol ) , allow 3 day entrance research facility . All medication ( include overthecounter medication , health supplement , herbal remedy St. John 's Wort extract ) must stop least 14 day prior first dose . The use limit amount acetaminophen ( â‰¤ 2 g/day ) permit . 8 . Participation drug study within 60 day prior drug administration . Participation 3 drug study 10 month precede start study . 9 . Donation 50 mL blood ( whole blood blood component ) within 60 day prior drug administration . 10 . History alcohol abuse drug addiction ( include soft drug like cannabis product ) 11 . Positive screen drug abuse ( opiate , methadone , cocaine , amphetamine , cannabinoids ) , barbiturates , benzodiazepine , tricyclic antidepressant alcohol 12 . Intake 24 unit alcohol per week ( one unit alcohol equal approximately 250 mL beer , 100 mL wine 35 mL spirit ) 13 . Positive screen hepatitis B surface antigen ( HBsAg ) 14 . Positive screen anti hepatitis C virus ( HCV ) 15 . Positive screen anti human immunodeficiency virus 1 2 ( HIV 1/2 ) 16 . Illness within 5 day prior drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>healthy male volunteer</keyword>
	<keyword>fast fed state</keyword>
</DOC>